Company Analysis

Iovance Biotherapeutics, Inc. (IOVA)

Nasdaq: IOVA · Biological Products, (No Diagnostic Substances) · San Carlos, CA · filing with the SEC since 2008
Grade6.0
◀ Past 7.0● Present 6.1▶ Future 5.0
2 est.

Who runs Iovance Biotherapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Vogt Frederick G
Interim CEO & General Counsel. First filing Oct 2017, latest Sep 10, 2026, 3 filings in all.
Officers reporting now
7
of 11 people with a filing in the last fifteen months
Directors reporting now
4
29 people on the record since 2011
Officerssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Kirby Daniel GordonChief Commercial OfficerFeb 2025Nov 12, 2026none
Roche Corleen M.Chief Financial OfficerAug 2025Nov 10, 2026none
Berkowitz NoahChief Medical OfficerOct 2026Oct 2, 2026none
Vogt Frederick GInterim CEO & General CounselOct 2017Sep 10, 2026none
Bilinsky IgorChief Operating OfficerMar 2021Sep 10, 2026none
Puri Raj K.Chief Regulatory OfficerDec 2024Sep 10, 2026none
Graf Finckenstein FriedrichChief Medical OfficerJul 2019Jun 9, 2026none
Directorssales are open-market, Nov 12, 2025 to Nov 12, 2026
NameRoleFirst filingLatest filingSales, 12 months
Countouriotis AthenadirectorJun 2019Jun 18, 2026none
Dukes Iain D.directorAug 2016Jun 18, 2026none
Maynard Ryan DdirectorFeb 2015Jun 18, 2026none
Weiser MichaeldirectorMar 2018Jun 18, 2026none
Earlier names on the record18, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton IOVA · research, not advice